A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma

被引：5
|
作者：
Dunne, Richard Francis
Ullman, Nicholas A.
Belt, Brian A.
Ruffolo, Luis I.
Burchard, Paul
Hezel, Aram F.
Zittel, Jason
Wang, Wenjia
Ramsdale, Erika E.
Kaul, Vivek
Zebala, John
Linehan, David
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Med, Div Gastroenterol, Rochester, NY 14642 USA
[4] Syntrix Pharmaceut, Auburn, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS631
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis
    Li, Yong
    Huang, Huiqin
    Ye, Xiangli
    Zeng, Bangwei
    Huang, Feijian
    Chen, Limin
    MEDICINE, 2024, 103 (16) : E37808
  • [22] A phase 1 dose escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies
    Hegde, Aparna
    Jayaprakash, Priyamvada
    Sumner, Elizabeth
    Di Nguyen
    Zain, Hira
    Piha-Paul, Sarina
    Karp, Daniel
    Rodon, Jordi
    Pant, Shubham
    Fu, Siqing
    Dumbrava, Ecaterina
    Yap, Timothy
    Subbiah, Vivek
    Bhosale, Priya
    Higgins, Jack
    Williams, Eric T.
    Wilson, Thomas F.
    Meric-Bernstam, Funda
    Curran, Michael
    Hong, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study
    Li, Qi-mei
    Sun, Qing-can
    Jian, Yan
    He, Jing-zhe
    Zhu, Hong-bo
    Hong, Chang
    Zeng, Lin
    Li, Rui-ning
    Wang, Jia-ren
    Li, Yan
    Chen, Li-ya
    Weng, Xie
    Liu, Li
    Dong, Han-zhi
    Xiao, Lu-shan
    Cui, Hao
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [24] Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study
    Qi-mei Li
    Qing-can Sun
    Yan Jian
    Jing-zhe He
    Hong-bo Zhu
    Chang Hong
    Lin Zeng
    Rui-ning Li
    Jia-ren Wang
    Yan Li
    Li-ya Chen
    Xie Weng
    Li Liu
    Han-zhi Dong
    Lu-shan Xiao
    Hao Cui
    Discover Oncology, 14
  • [25] Efficacy and safety of PD-1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: A multicenter retrospective study
    Wu, Zhiheng
    Zhu, Xudong
    Zhong, Xian
    Wang, Yiran
    Zheng, Yu
    Han, Weidong
    Pan, Hongming
    Yao, Junlin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (01)
  • [26] Comparison of efficacy and safety of PD-1 and PD-L1 antibodies in combination with hepatic arterial infusion chemotherapy and target therapy for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study.
    Xiong, Xinhao
    Wang, Qiaoxuan
    Dai, Wei
    Zhao, Rongce
    Mei, Jie
    Zheng, Zehao
    Gan, Junyu
    Xu, Longzhou
    Li, Jibin
    Zheng, Lie
    Wei, Wei
    Zhong, Jian-Hong
    Guo, Rongping
    Li, Shaohua
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 553 - 553
  • [27] Concurrent chemoradiotherapy with gemcitabine and S-1 for unresectable locally advanced pancreatic adenocarcinoma: A phase I study
    Ioka, T.
    Fukutake, N.
    Ikezawa, K.
    Tanaka, S.
    Nakamura, S.
    Nishiyama, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [28] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Callahan, Margaret K.
    Ott, Patrick Alexander
    Odunsi, Kunle
    Bertolini, Staphane V.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
    Hiroaki Yanagimoto
    Sohei Satoi
    Masayuki Sho
    Takahiro Akahori
    Tomohisa Yamamoto
    Satoshi Hirooka
    So Yamaki
    Masaya Kotsuka
    Hironori Ryota
    Shoichi Kinoshita
    Satoshi Nishiwada
    Minako Nagai
    Naoya Ikeda
    Koji Tsuta
    Yoshiyuki Nakajima
    Masanori Kon
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 35 - 41
  • [30] Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma
    Yanagimoto, Hiroaki
    Satoi, Sohei
    Sho, Masayuki
    Akahori, Takahiro
    Yamamoto, Tomohisa
    Hirooka, Satoshi
    Yamaki, So
    Kotsuka, Masaya
    Ryota, Hironori
    Kinoshita, Shoichi
    Nishiwada, Satoshi
    Nagai, Minako
    Ikeda, Naoya
    Tsuta, Koji
    Nakajima, Yoshiyuki
    Kon, Masanori
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) : 35 - 41
12345